Skip directly to Accessibility Notice

How to Purchase

Individual Investors

Subscribe to email updates

Subscribe Now

Financial Professionals

GNRX
VanEck Vectors Generic Drugs ETF

This Fund is expected to cease trading at market close on April 5, 2019. Shareholders who do not sell their holdings on or before April 5, 2019 and continue to hold their shares through the liquidation date are expected to receive a liquidating distribution on or about April 12, 2019. Please see the press release and FAQ below for more information.

Press Release
FAQ

Fund Description

VanEck Vectors® Generic Drugs ETF (GNRX) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Indxx Global Generics & New Pharma Index (IGNRXT), which is intended to track the overall performance of companies that derive a significant proportion of their revenues or that have the potential to derive a significant proportion of their revenues from the generic drug industry, or that have a primary business focus on the generic drug industry.

 
 

  • Fund Ticker

    GNRX
  • Exchange

    NASDAQ
  • Commencement

    01/12/2016
  • ETF Structure

    Physical
  • Administrator

    Van Eck Associates
  • Custodian

    Bank of New York Mellon
  • Index Ticker

    IGNRXT
  • Index Rebalancing

    Semi-Annual

 
as of 03/22/19

  • 30-Day SEC Yield1

    0.43%
  • Total Net Assets

    $3.3M
  • Number of Holdings

    39
  • Options

    Expected
  • Gross Expense Ratio2

    3.33%
  • Net Expense Ratio/TER2

    0.55%
  • Distribution Frequency

    Annual
  • Next Distribution Date

    12/20/19

Key Points

Industry may benefit from ongoing push to lower health care costs


The only ETF offering global exposure to generic drug producers


Positioned to take advantage of the expected growth of biosimilars

 

Trading Information

  • Fund Ticker

    GNRX
  • Index Total Return Ticker

    IGNRXT
  • NAV

    GNRXNV
  • Intraday NAV (IIV)4

    GNRXIV
  • Shares Outstanding

    150,000
  • Estimated Cash

    GNRXEU
  • Total Cash

    GNRXTC
  • CUSIP

    92189F577
  • ISIN

    US92189F5778
Source: Bloomberg

Fees and Expenses2

  • Management Fee

    0.50%
  • Other Expenses

    2.83%
  • Gross Expense Ratio

    3.33%
  • Fee Waivers and
    Expense Reimbursement

    -2.78%
  • Net Expense Ratio/TER2

    0.55%
2Expenses for GNRX are capped contractually at 0.55% until February 1, 2020. Cap excludes acquired fund fees and expenses, interest expense, trading expenses, taxes and extraordinary expenses.

Prices as of 03/22/19

NAV/
Last Price
Volume
30-Day Avg./
Last Trading Day
Daily Change
NAV/
Last Price
YTD Change
NAV/
Last Price
Premium/
Discount
Prem/Discount
Distribution Charts
NAV &
Prem/Discount
History
NAV
Chart
GNRX $22.13
$21.91
328
110
-$0.59 / -2.58%
$-0.65 / -2.89%
+6.18%
+5.85%
$-0.22
-0.98%

Performance History: Average Annual Total Returns* (%)

1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
01/12/16
GNRX (NAV) -0.50 -8.63 5.76 -10.78 -1.16 -- -- -3.59
GNRX (Share Price) -0.05 -8.74 6.57 -11.59 -1.49 -- -- -3.55
IGNRXT (Index) -0.26 -8.47 5.82 -10.75 -0.58 -- -- -2.94
Performance Differential (NAV - Index) -0.24 -0.16 -0.06 -0.03 -0.58 -- -- -0.65
1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
01/12/16
GNRX (NAV) -13.61 -17.77 -14.84 -14.84 -- -- -- -5.57
GNRX (Share Price) -14.37 -18.35 -14.79 -14.79 -- -- -- -5.78
IGNRXT (Index) -13.51 -17.71 -14.51 -14.51 -6.61 -- -- -4.92
Performance Differential (NAV - Index) -0.10 -0.06 -0.33 -0.33 -- -- -- -0.65

Top 10 Holdings (%) as of 02/28/19 Daily Holdings

Total Holdings: 39
Swipe
to view
full data
Holding Name
Ticker
Shares Market Value
(US$)
% of Net
Assets
Pfizer Inc
PFE US
7,232
313,507 9.48
Iqvia Holdings Inc
IQV US
2,091
292,949 8.86
Celltrion Inc
068270 KS
1,211
219,686 6.65
Lonza Group Ag
LONN SW
769
213,956 6.47
Teva Pharmaceutical Industries Ltd
TEVA US
10,172
171,195 5.18
Sun Pharmaceutical Industries Ltd
SUNP IN
22,992
143,898 4.35
Mylan Nv
MYL US
5,168
136,384 4.13
Kyowa Hakko Kirin Co Ltd
4151 JP
6,000
114,811 3.47
Sino Biopharmaceutical Ltd
1177 HK
130,500
113,245 3.43
Cspc Pharmaceutical Group Ltd
1093 HK
64,000
109,268 3.31
Top 10 Total (%) 55.33
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%) as of 02/28/19

  • Country

    % of Net Assets
  • UNITED STATES

    38.51
  • INDIA

    17.28
  • CHINA

    9.83
  • SOUTH KOREA

    8.11
  • JAPAN

    7.74
  • SWITZERLAND

    6.47
  • ISRAEL

    5.18
  • JORDAN

    1.67
  • INDONESIA

    1.55
  • SOUTH AFRICA

    1.41
  • FINLAND

    1.16
  • HUNGARY

    1.13
  • Other/Cash

    -0.03

Sector Weightings (%) as of 02/28/19

  • Sector

    % of Net Assets
  • Health Care

    96.9
  • Materials

    3.1
  • Other/Cash

    0.0